New England Journal of Medicine

The New England Journal of Medicine (NEJM) is an English-language peer-reviewed medical journal published by the Massachusetts Medical Society. It describes itself as the oldest continuously published medical journal in the world. The journal publishes editorials, papers on original research, review articles, correspondence, and case reports, and has a special section called "Images in Clinical Medicine". In September 1811, John Collins Warren, a Boston physician, along with James Jackson, submitted a formal prospectus to establish the New England Journal of Medicine and Surgery and Collateral Branches of Science as a medical and philosophical journal. Subsequently, the first issue of the New England Journal of Medicine and Surgery and the Collateral Branches of Medical Science was published in January 1812. The journal was published quarterly. On April 29, 1823, another publication, the Boston Medical Intelligencer, appeared under the stewardship of Jerome V.C. Smith. The Intelligencer ran into financial troubles in the spring of 1827, and the editors of the New England Journal of Medicine and Surgery and the Collateral Branches of Medical Science purchased it in February 1828

Publisher
Massachusetts Medical Society
Country
United States
History
The New England Journal of Medicine and Surgery (1812–1826);
The New England Medical Review and Journal (1827);
The Boston Medical and Surgical Journal (1828–1927);
The New England Journal of Medicine (1928–present)
Impact factor
53.484 (2010)
Some content from Wikipedia, licensed under CC BY-SA

Polls show deep partisan divide over Affordable Care Act

A comprehensive analysis of data from 27 public opinion polls conducted by 14 organizations, including a poll in September of those most likely to vote, shows an electorate polarized by political party when it comes to the ...

Oct 29, 2014
popularity not rated yet | comments 0

FOLFOXIRI plus bevacizumab ups outcome in metastatic CRC

(HealthDay)—For patients with untreated metastatic colorectal cancer, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab improves outcome versus fluorouracil, ...

Oct 23, 2014
popularity not rated yet | comments 0